Lung transplant injury drives chronic lung allograft dysfunction via recruitment ofmonocyte-derived alveolar macrophages

肺移植损伤通过单核细胞衍生的肺泡巨噬细胞的募集导致慢性肺同种异体移植功能障碍

基本信息

  • 批准号:
    10034029
  • 负责人:
  • 金额:
    $ 72.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary: For many patients with advanced lung disease, lung transplantation remains the only viable therapeutic option to extend life. Yet the 5-year survival for lung transplant patients is 54%, the worst among solid organ transplant recipients. Chronic lung allograft dysfunction (CLAD) is the leading cause of morbidity and late mortality after lung or heart-lung transplantation. Hence, identification of biomarkers and novel therapeutic targets is essential to prevent or treat CLAD and extend survival after lung transplantation. While multiple factors contribute to CLAD, early events after the lung transplant procedure play a crucial role in setting the stage for subsequent CLAD. These include surgical trauma and ischemia-reperfusion injury that activates circulating and resident immune cells followed by the endothelial injury and immune cell extravasation. We have reported that monocytes, recruited to the injured lung, can establish a long-term residency and differentiate into pathogenic monocyte-derived alveolar macrophages. We have causally linked monocyte-derived alveolar macrophages to tissue-remodeling and fibrosis (resembling CLAD) using a genetic deletion strategy. Moreover, using unbiased single-cell transcriptomic profiling (RNA-seq) of explanted lung tissue from the patients with pulmonary fibrosis and biopsies of the donor lung (both obtained during lung transplantation by lung transplant surgeon – Ankit Bharat, key contributor to this proposal), we identified a distinct population of pathogenic alveolar macrophages exclusively present in patients with pulmonary fibrosis. Our computational analyses of single-cell RNA-seq data suggest that monocyte-derived alveolar macrophages are guided to their new pathogenic niches via plexin D1/signaling and are uniquely maintained by M-CSF/M- CSFR signaling. Consistent with this hypothesis, targeting M-CSF/M-CSFR signaling specifically eliminated monocyte-derived alveolar macrophages and ameliorated pathology. We present preliminary data from mouse models and patients with chronic lung allograft dysfunction supporting relevance of this mechanism for CLAD. We will thus use mouse models and samples from lung transplant patients to test the hypothesis that pathogenic monocyte-derived alveolar macrophages, recruited during the initial peri-transplant injury, establish long term residency via plexin D1/semaphorin signaling and are maintained via M-CSF/M- CSFR signaling to drive CLAD in three interrelated aims: Aim 1: To determine whether monocyte-derived alveolar macrophages recruited to the transplanted lung within day of the transplant are maintained by M-CSF/M-CSFR signaling. Aim 2: To determine whether pathogenic monocyte-derived alveolar macrophages are localized to regions of lung fibrosis lung via plexin D1/semaphorin signaling. Aim 3: To determine whether the emergence of aberrant alveolar macrophages with increased expression of PLXND1 and autocrine M-CSF/M-CSFR signaling can be identified in BAL fluid from patients with early CLAD.
项目总结:对于许多晚期肺部疾病患者,肺移植仍然是唯一的治疗方法

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander Misharin其他文献

Alexander Misharin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander Misharin', 18)}}的其他基金

Monocyte-derived alveolar macrophage drives inflammatory response to lung ozone exposure
单核细胞来源的肺泡巨噬细胞驱动对肺臭氧暴露的炎症反应
  • 批准号:
    10689120
  • 财政年份:
    2022
  • 资助金额:
    $ 72.83万
  • 项目类别:
The Cell Phenotyping and Mouse Core
细胞表型和小鼠核心
  • 批准号:
    10269673
  • 财政年份:
    2021
  • 资助金额:
    $ 72.83万
  • 项目类别:
The Cell Phenotyping and Mouse Core
细胞表型和小鼠核心
  • 批准号:
    10696959
  • 财政年份:
    2021
  • 资助金额:
    $ 72.83万
  • 项目类别:
Lung transplant injury drives chronic lung allograft dysfunction via recruitment ofmonocyte-derived alveolar macrophages
肺移植损伤通过单核细胞衍生的肺泡巨噬细胞的募集导致慢性肺同种异体移植功能障碍
  • 批准号:
    10469545
  • 财政年份:
    2020
  • 资助金额:
    $ 72.83万
  • 项目类别:
Lung transplant injury drives chronic lung allograft dysfunction via recruitment ofmonocyte-derived alveolar macrophages
肺移植损伤通过单核细胞衍生的肺泡巨噬细胞的募集导致慢性肺同种异体移植功能障碍
  • 批准号:
    10247694
  • 财政年份:
    2020
  • 资助金额:
    $ 72.83万
  • 项目类别:
Lung transplant injury drives chronic lung allograft dysfunction via recruitment ofmonocyte-derived alveolar macrophages
肺移植损伤通过单核细胞衍生的肺泡巨噬细胞的募集导致慢性肺同种异体移植功能障碍
  • 批准号:
    10682438
  • 财政年份:
    2020
  • 资助金额:
    $ 72.83万
  • 项目类别:
Technology Core
技术核心
  • 批准号:
    10326812
  • 财政年份:
    2018
  • 资助金额:
    $ 72.83万
  • 项目类别:
Technology Core
技术核心
  • 批准号:
    10097980
  • 财政年份:
    2018
  • 资助金额:
    $ 72.83万
  • 项目类别:
Activating proteostasis in aging resident macrophages to prevent muscle and cognitive dysfunction after pneumonia
激活老化常驻巨噬细胞中的蛋白质稳态,以预防肺炎后的肌肉和认知功能障碍
  • 批准号:
    10197744
  • 财政年份:
    2015
  • 资助金额:
    $ 72.83万
  • 项目类别:
Monitoring the aging lung using genomics, proteomics and informatics
利用基因组学、蛋白质组学和信息学监测肺部老化
  • 批准号:
    10620762
  • 财政年份:
    2015
  • 资助金额:
    $ 72.83万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 72.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 72.83万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 72.83万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 72.83万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 72.83万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 72.83万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 72.83万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 72.83万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 72.83万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 72.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了